Loading...

Fusion Antibodies PLC
LSE:FAB

Watchlist Manager
Fusion Antibodies PLC Logo
Fusion Antibodies PLC
LSE:FAB
Watchlist
Price: 31.5 GBX Market Closed
Updated: Mar 25, 2023

Intrinsic Value

FAB doesn't have a meaningful market cap.

The intrinsic value of one FAB stock under the Base Case scenario is 57.39 GBX. Compared to the current market price of 31.5 GBX, Fusion Antibodies PLC is Undervalued by 45%.

The Intrinsic Value is calculated as the average of the two valuation methods:

FAB Intrinsic Value
Base Case
57.39 GBX
Undervaluation 45%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

FAB Profitability Score
Profitability Due Diligence

Fusion Antibodies PLC's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

Negative 3-Year Average ROE
Negative 3-Year Average ROIC
Negative Free Cash Flow
Negative Operating Income
19/100
Profitability
Score

Fusion Antibodies PLC's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

FAB Solvency Score
Solvency Due Diligence

Fusion Antibodies PLC's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

Low Interest Coverage
High Altman Z-Score
Long-Term Liabilities
Short-Term Liabilities
62/100
Solvency
Score

Fusion Antibodies PLC's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

Financials

Balance Sheet Decomposition
Fusion Antibodies PLC

Current Assets 3.2M
Cash & Short-Term Investments 1.2M
Receivables 1.5M
Other Current Assets 552k
Non-Current Assets 743k
PP&E 743k
Current Liabilities 1.1M
Accounts Payable 1.1M
Other Current Liabilities 83k
Non-Current Liabilities 270k
Long-Term Debt 250k
Other Non-Current Liabilities 20k
Efficiency
44%
Gross Margin
-46%
Operating Margin
-41%
Net Margin
-24%
FCF Margin
Other

FAB Capital Structure
Fusion Antibodies PLC

Market Capitalization 8.2M GBX
Total Debt 250k GBX
Minority Interest 0 GBX
Preferred Equity 0 GBX
Cash and Equivalents 1.2M GBX
Short-Term Investments 0 GBX
Enterprise Value 7.2M GBX

Wall St
Price Targets

FAB Price Targets Summary
Fusion Antibodies PLC

There are no price targets for FAB.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

FAB Competitors
Fusion Antibodies PLC

FAB Suppliers & Customers
Fusion Antibodies PLC

Suppliers Map
Customers Map

Shareholder Return

FAB Return Decomposition
Main factors of price return

Price Return Decomposition
is not available

It is impossible to break down the market cap return as the net margin from 5 years ago is negative.

What is price return decomposition?

FAB Price
Fusion Antibodies PLC

1M 1M
-37%
6M 6M
-39%
1Y 1Y
-48%
3Y 3Y
-60%
5Y 5Y
-73%
Annual Price Range
31.5
52w Low
29
52w High
96
Price Metrics
Average Annual Return 9.27%
Standard Deviation of Annual Returns 51.5%
Max Drawdown -85%
Shares Statistics
Market Capitalization 8.2M GBX
Shares Outstanding 26 014 946
Percentage of Shares Shorted
N/A

Company Profile

Fusion Antibodies PLC Logo
Fusion Antibodies PLC

Country

United Kingdom

Industry

Life Sciences Tools & Services

Market Cap

8.2M GBP

Dividend Yield

0%

Description

Fusion Antibodies Plc engages in the provision of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The company is headquartered in Belfast, Northern Ireland and currently employs 54 full-time employees. The company went IPO on 2017-12-18. The firm offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The principal activity of the Company is the research, development and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. The Company’s services include discovery, engineering and supply. Discovery services includes creation, screening and sequencing of monoclonal antibodies for therapeutic and diagnostic applications. Engineering services includes maximizing the performance of an antibody drug including CDRx humanization, Antibody Developability by Design (ADDTM) and RAMP. Supply services includes the production of material for clinical production or further research, including cGMP ready stable cell line development and transient expression.

Contact

NORTHERN IRELAND
Belfast
Springbank Industrial Estate, 1 Springbank Road
+442890432800.0
https://fusionantibodies.com/

IPO

2017-12-18

Employees

54

Officers

CFO, Company Sec. & Director
Mr. James Fair
Chief Scientific Officer & Director
Dr. Richard John Buick Ph.D.
CEO & Director
Dr. Adrian Kinkaid Ph.D.
Founder
Prof. Jim Johnston
Director of Operations
Mr. Hugh Morgan Ph.D.
Consultant
Dr. Paul Gerard Kerr

See Also

Similar Stocks
What is the Intrinsic Value of one FAB stock?

The intrinsic value of one FAB stock under the Base Case scenario is 57.39 GBX.

Is FAB stock undervalued or overvalued?

Compared to the current market price of 31.5 GBX, Fusion Antibodies PLC is Undervalued by 45%.